Search results
Showing 31 to 45 of 143 results for sclerosis
Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)
Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults.
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)
Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease.
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults.
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)
Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults.
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)
Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351
In development Reference number: GID-TA11333 Expected publication date: TBC
Evidence-based recommendations on natalizumab (Tysabri) for treating highly active relapsing–remitting multiple sclerosis in adults.
Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis (HTG558)
Evidence-based recommendations on pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis in adults. This involves spraying the inside of the peritoneal cavity with chemotherapy.
View recommendations for HTG558Show all sections
Masitinib for treating amyotrophic lateral sclerosis [ID967]
Discontinued Reference number: GID-TA10157
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]
Discontinued Reference number: GID-TA10427
Topic prioritisation
Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)
Evidence-based recommendations on cladribine (Mavenclad) for treating active relapsing forms of multiple sclerosis in adults.
Tolebrutinib for treating primary progressive multiple sclerosis [ID6574]
Topic prioritisation
Tolebrutinib for treating primary progressive multiple sclerosis [TSID12166]
Topic prioritisation